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Abstract
Bone marrow cytomorphology and histopathology are the cornerstones for the initial diagnosis of myelodysplastic syndromes (MDS) and other related myeloid 
disorders. They provide a rapid first insight into diagnostic categories and thus help in clinical decision making. However, difficulties in the morphologic assessment 
of MDS exist due to inter- and intra-observer variability. In this study, we directly compared the results of cytomorphology and histopathology obtained in a real-
world diagnostic scenario in 90 patients with myeloid malignancies aiming to evaluate their validity for diagnosing and classifying various myeloid malignancies. 
While both techniques placed 80% of our bone marrow samples into the same diagnostic category and thus showed a good correlation, our study also demonstrates 
the limitations in correlating marrow cytomorphology and histopathology, even following stringent and repetitive diagnostic assessments. This was particularly true 
for CMML, where not only additional diagnostic tools such as molecular genetics or clinical evaluation but also the analysis of the peripheral blood smears aided in 
finding the correct diagnosis. Overall, our data emphasize the need for a comprehensive diagnostic review in a patient-for-patient setting when a myeloid malignancy 
is suspected or confirmed. We propose that the combination of cytomorphologic and histopathologic assessment with clinical, laboratory, and genetic parameters is 
essential in achieving high diagnostic accuracy in an interdisciplinary setting.
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Introduction 
Myelodysplastic syndromes (MDS) represent clonal hematopoietic 
stem cell disorders with cytopenia, varying degrees of dysplasia, 
and frequent transformation towards secondary acute myeloid 
leukemia (s-AML) [1]. Cytomorphology, histopathology, and 
immunohistochemistry are the major initial diagnostic cornerstones for 
MDS [2] as well as related myeloid disorders such as myelodysplastic/ 
myeloproliferative neoplasm (MDS/MPN)-overlap conditions 
including chronic myelomonocytic leukemia (CMML). As interpreting 
cytomorphology and histopathology remains challenging in many 
cases, repeated follow-up investigations may be necessary to confirm 
MDS diagnosis. Considering the increasing frequency of MDS due to 
aging of the general population [3-6] rapid and efficient diagnostics gain 
importance for myeloid malignancies. Next-generation sequencing 
(NGS) was integrated into the contemporary diagnostic process [7-9], 
but comes with significant costs, requires an intensive post-analytical 
work-up, and should always be aligned with other diagnostic methods 
[10]. Furthermore, the phenomenon of clonal hematopoiesis of 
indeterminate potential [11,12] emphasizes that somatic mutations per 
se do not necessarily confirm MDS diagnosis.
Difficulties in the morphologic diagnosis of MDS result from 
inter- and intra-observer variability in the determination of unilineage 
dysplasia [13,14], especially in the absence of ring sideroblasts or 
increased blasts. We here compared the results of cytomorphology 
and histopathology obtained in a real-world diagnostic scenario in 90 
patients with MDS and the spectrum of related disorders aiming to 
evaluate their validity for diagnosing and classifying various myeloid 
malignancies.
Materials and Methods
We included 90 patients diagnosed with a myeloid malignancy 
at the university hospitals Bern and Munich in the period of 2007–
2017. Requirement for inclusion in the retrospective study was the 
availability of both bone marrow cytomorphology and histopathology. 
The following categories were considered: all subtypes of MDS and 
MDS/MPN as well as CMML and s-AML (Tables 1 and 2). Patients 
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consented with use of coded laboratory data for research purposes. 
Ethics approval was obtained from the local Ethic Commissions. 
During the routine diagnostic process, bone marrow aspirates 
(cytomorphology) were prospectively evaluated by two hematologists 
and bone marrow core biopsies (histopathology) specimens by 
two hematopathologists within the usual diagnostic workflow. 
The hematology and hematopathology routine assessments were 
independent. For the purpose of this study, the diagnoses obtained 
at the primary investigation were independently re-assessed by three 
recognized experts in cyto- and histomorphology of myeloid disorders 
(LE, VUB, YB) integrating further laboratory results and the clinical 
background. All investigators of the study were blinded for the previous 
classifications. Bone marrow samples were re-examined for dysplastic 
features using a pre-defined assessment form based on WHO criteria 
[1], as shown in Supplemental Table S1. Following this diligent re-
evaluation process, the conclusive diagnoses derived at the primary 
routine assessment were slightly modified in a small proportion of cases 
either for the cytomorphologic or for the histopathologic categorization 
(10 cases; 11.1% of the study cohort), whereas the vast majority of cases 
remained categorized as before. Thus, the focus was the real-world 
diagnostic scenario in a university setting that was later re-evaluated 
(and modified in some cases) as part of this study. Only few samples 
(n=6) had been excluded due to insufficient material quality. 
For cytomorphology, bone marrow slides were May-Grünwald-
Giemsa (MGG) stained. Forty-five cases underwent iron staining 
(Berliner Blau) and a proportion were analyzed for myeloperoxidase 
(n=34) and non-specific esterase (n=33). Cytomorphology classification 
followed WHO, 2008; categorization of a hematopoietic lineage as 
dysplastic required ≥ 10% dysplastic cells [1]. For histopathology, 
biopsy specimens were stained in the original diagnostic workup by 
Hematoxilin and Eosin (H&E), periodic-Acid Schiff (PAS), iron, and 
Gomori silver stain (Tissue-Tek Prisma, Automated Slide Stainer, 
Sakura Europe). Immunohistochemistry (BOND III, Leica Biosysterms, 
Nussloch, Germany) was including CD3, CD42b (Novocastra), 
CD20, CD34, CD68, CD117, Myeloperoxidase (Dako), CD138 (AbD 
Serotec), CD71 (Cell Marque). Details of the parameters assessed by 
both techniques are given in Supplemental Table S1. A proportion of 
patients (n=39) was analyzed by molecular methods including PCR-
based methods, Sanger sequencing, or increasingly next-generation 
sequencing (NGS). Cytogenetics were available in 85 patients (94.4% 
of all cases). More detailed information is given in Table 1 and Table S3. 
Results of flow cytometry were sometimes raised, but not integrated 
into our study. Statistics were calculated by SPSS 24 (Statistical Package 
for Social Science, IBM®). Correlation coefficients were calculated 
according to Spearman. Frequencies were compared by chi square. 
Results
Cytomorphology on bone marrow aspirates revealed the 
following diagnoses according to WHO 2008 [1] (Table 2): refractory 
anemia with excess blasts (RAEB, n=29/90, 32.2%), followed by s-AML 
(n=21, 23.3%), refractory cytopenia with multilineage dysplasia 
(RCMD, n=15, 16.7%), and suspected MDS (n=8, 8.9%). In three 
patients (n=3, 3.3%) MDS/MPN overlap was diagnosed. Nine patients 
(n=9, 10.0%) were classified as CMML. Two patients were diagnosed 
as hypoplastic MDS (n=2, 2.2%), two as refractory anemia with ring 
sideroblasts (RARS), or as refractory anemia with ring sideroblasts 
with thrombocytosis (RARS-T, n=1, 1.1% each), and one patient had 
MDS with isolated 5q-deletion (n=1, 1.1%).
We grouped all cases to the following five diagnostic categories: 1) 
MDS without increase in blasts (RCMD, RCMD-RS, RARS, RARS-T, 
hypoplastic MDS, MDS with 5q deletion, MDS/MPN-overlap, suspected 
MDS): n=31/90 (34.4%); 2) MDS with increased blasts (RAEB-1/-2): 
n=29 (32.2%); 3) s-AML: n=21 (23.3%); 4) CMML (CMML-1/-2): n=9 
(10.0%). No case was assigned to category 5 (reactive changes).
Parameter Number (%)
Patients 90 (100.0%)
At diagnosis 87 (96.7)
At follow-up 3 (3.3)
Males/females (ratio) 56/34 (1.6)
Age, years, median (range) 70 (21 – 87)
Peripheral blood parameters
WBC, G/L, median (range) 3.4 (0.1-87)
Hb, g/L, median (range) 91 (58-153)
Thrombocytes, g/l, median (range) 57 (1-958)
IPSS risk group (in MDS pts) 59 (100.0%)
Low 18 (30.5)
intermediate-1 22 (37.3)
intermediate-2 17 (28.8)
High 2 (3.4)
IPSS-R risk group (in MDS pts) 55 (100.0%)
Very poor 13 (23.6)
Poor 9 (16.4)
Intermediate 15 (27.3)
Good 17 (30.9)
Very good 1 (1.8)
Cytogenetics 85 (100.0%)
Normal karyotype 30 (35.3)
Aberrant karyotypes 55 (64.7)
-Y 3 (5.5)
-5/del(5q) 4 (7.3)
del(20q) 3 (5.5)
-7/del(7q) 10 (18.2)
Complex (≥ 3) aberrations 17 (30.9)
Other aberrations 18 (32.7)
Table 1. Demographic features, peripheral blood parameters, risk profiles, and genetic 
results in the study cohort
Del: deletion, Hb: Hemoglobin; IPSS: International Prognostic Scoring System; IPSS-R: 
Revised International Prognostic Scoring System; WBC: White blood cells.
Number (%)
Parameter Cytomorphology Histopathology
Diagnostic category 1 N=31 (%) N=34 (%)
RCMD
RARS
RARS-T
Hypoplastic MDS
MDS with isolated 5q deletion
MDS/MPN overlap
Suspected MDS
15 (16.7)
1 (1.1)
1 (1.1)
2 (2.2)
1 (1.1)
3 (3.3)
8 (8.9)
10 (11.1)
-
-
2 (2.2)
1 (1.1)
1 (1.1)
20 (22.2)
Diagnostic category 2 N=29 (%) N=25 (%)
RAEB-1
RAEB-2
14 (15.6)
15 (16.7)
9 (10.0)
16 (17.8)
Diagnostic category 3 N=21 (%) N=23 (%)
s-AML 21 (23.3) 23 (25.6)
Diagnostic category 4 N=9 (%) N=6 (%)
CMML-1
CMML-2
4 (4.4)
5 (5.6)
5 (5.6)
1 (1.1%)
Diagnostic category 5 N=0 (%) N=2 (%)
Reactive changes - 2 (2.2)
Table 2. Classification of the disorders according to cytomorphology and histopathology
CMML: Chronic myelomonocytic leukemia; MDS: Myelodysplastic syndrome; RCMD: 
Refractory cytopenia with multilineage dysplasia; RAEB: Refractory anemia with excess 
blasts; RARS-T: Refractory anemia with ring sideroblasts and thrombocytosis; s-AML: 
Secondary acute myeloid leukemia.
Engelbrecht L (2019) Correlation of cytomorphology and histopathology in the diagnostic process of myeloid malignancies
 Volume 4: 3-5Hematol Med Oncol, 2019         doi: 10.15761/HMO.1000190
By histopathology on bone marrow specimens, the most common 
diagnoses in order of decreasing frequency were (Table 2): MDS RAEB 
(n=25/90, 27.8%), s-AML (n=23, 25.6%), suspected MDS (n=20, 
22.2%), and MDS RCMD (n=10, 11.1%). CMML was diagnosed in 
six cases (6.7%). A hypoplastic MDS was detected in two cases (2.2%). 
Two cases were considered reactive (2.2%). One patient had MDS with 
isolated 5q-deletion, one showed MDS/MPN overlap (1.1% for each). 
Following the categories above, we found the following frequencies by 
histopathology: 1) MDS without blast increase: n=34/90 (37.8%); 2) 
MDS with blast increase: n=25 (27.8%); 3) s-AML: n=23 (25.6%); 4) 
CMML: n=6 (6.7%); 5) reactive changes: n=2 (2.2%).
To compare the classification by cytomorphology and 
histopathology, cases were assigned to the above five categories, 
primarily based on cytomorphology. The highest concordance rate was 
found for “s-AML” (category 3) as cytomorphologic assessment was 
confirmed in 20/21 cases (95.2%) by histopathology. This was followed 
by a concordance rate of 83.9% in the category “MDS without increase 
in blasts” (category 1; 31 cases classified accordingly by cytomorphology 
were supported by the absence of blast increase and the existence of 
dysplastic features by histopathology in 26 cases). For category 2 “MDS 
with increase in blasts” the concordance rate was 72.4% (29 cases 
classified accordingly by cytomorphology were corresponding in 21 
cases to histopathology, as there was blast increase between 5-19%). The 
correspondence rate was lowest for “CMML” (category 4; detected by 
cytomorphology in nine cases; matched by histopathology in five cases, 
55.6%). Thus, cytomorphology and histopathology were concordant in 
72/90 cases (80.0%) when the total cohort was summarized. 
In 18/90 patients (20.0%), the diagnostic categories were differing 
by cytomorphology and histopathology: by cytomorphology, they 
were categorized as “MDS with increase in blasts” (category 2; 
n=8/18), “MDS without increase in blasts” (category 1; n=5), followed 
by “CMML” (category 4; n=4), and “s-AML” (category 3; n=1). By 
histopathology, most frequent was “MDS without increase in blasts” 
(category 1; n=8/18) and “MDS with increase in blasts” (category 2; 
n=4), followed by “s-AML” (category 3; n=3), “reactive changes” 
(category 5; n=2), and “CMML” (category 4; n=1). These 18 cases 
could be summarized as follows: 1) differing results due to difficulties 
in determining blast percentages: n=6; 2) different results due to poor 
marrow sample quality: n=6; 3) different results due to difficulties in 
determining monocytes/monocytic blasts by histopathology: n=4; and 
4) different results due to classification as RCMD in cytomorphology 
and as reactive changes in histopathology: n=2. More detailed 
information about the 18 discrepant cases between cytomorphology 
and histopathology are given in Figures 1a-c and Supplemental 
Table S4. Supplementary diagnostics like cytogenetics and molecular 
analyses (if available) were considered for the conclusive diagnosis 
(Table S4). Focusing on MDS cases as diagnosed by cytomorphology 
and/or histopathology, the frequency of TP53 mutations was n=2/8 in 
our cohort. The respective analyses were driven by the physicians in 
charge and should not be considered representative due to the limited 
sample size. In the literature, frequencies of 8.1 to 14.0% are given for 
TP53 mutations in MDS [15,16].
There was a good correlation between both methods for investigating 
dysplasia in the three hematopoietic lineages (granulopoiesis: 
χ2(1)=1.176, p=0.278; erythropoiesis: χ2 not applicable, as all cases were 
dysplastic by cytomorphology; megakaryopoiesis: χ2(1)=1.587, p=0.208) 
(Table S2A). Correlation of cytomorphology and histopathology for 
overall cellularity (proportion of hematopoietic tissue to adipocytes) 
and for cellularity of the three hematopoietic lineages was limited 
(overall cellularity: χ2(4)=7.942, p=0.094; granulopoiesis: χ2(4)=13.252, 
p=0.010; erythropoiesis: χ2(4)=26.764, p<0.001; megakaryopoiesis: 
χ2(4)=36.180, p<0.001) (Supplemental Table S2B). Cytomorphology 
and histopathology were concordant in the subcategorization of bone 
marrow blasts (thresholds <5%, 5 to 9%, 10 to 19%, and ≥20%) in only 
two thirds of the 82 cases that were evaluable by both techniques for 
this parameter (n=54/82; 65.9%, r=0.69, p<0.0001). Assignment of 
cells to the monocytic lineage revealed a similar lower concordance 
between cytomorphology and histopathology (n=40/58; 69.0%, r=0.31, 
p=0.0197; only 58 cases were evaluable due to limited availability of 
immunohistochemistry for CD68 and due to limited sample quality).
Discussion
In this study, bone marrow samples from patients with different 
myeloid entities underwent a standardized re-evaluation of the initial 
69 years old, male patient, final diagnosis: RCMD in CM; reactive in HP 
CM1 
 HP1,2 
 
Figures 1. Examples of different diagnoses by cytomorphology and histopathology. 
Figure 1a. Patient’s diagnosis was RCMD by cytomorphology but reactive changes by 
histopathology.
1400 x Zoom, Staining in CM: May-Grünwald-Giemsa, staining of first picture in HP: 
Hematoxillin and Eosin, 2Second picture of HP: Immunhistochemistry CD34
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routine diagnostic assessment by experienced hematologists and 
hematopathologists. The “real-world” diagnostic classification of bone 
marrow samples was retrospectively re-evaluated in the context of 
this study. Both techniques - cytomorphology and hematopathology - 
placed 80% of bone marrow samples into the same diagnostic category 
and thus showed a good correlation. Interestingly, the concordance 
rate was highest in “s-AML“ followed by “MDS without increase 
in blasts”, and “MDS with increase in blasts” (95% vs. 84% vs. 72% 
of all cases). In contrast, the concordance rate was low for “CMML“ 
with 56% only. This demonstrates the limitations of both phenotypic 
methods for some cases of myeloid malignancies and underscores their 
complementarity. Furthermore, this emphasizes in particular the value 
of molecular diagnostics for the diagnosis of CMML, with >90% of 
patients carrying mutations [17]. Due to the period of study ranging 
back as far as 2007, only a proportion of the respective patients had 
been investigated by NGS. 
As demonstrated in our cohort, it was possible to assign a conclusive 
diagnostic entity in 20% of the cases with discrepant initial evaluations 
based on the above-mentioned parameters. Moreover, hematology and 
histopathology showed limited concordance regarding the assessment 
of blasts, monocytic cells, and cellularity, whilst there was a high 
concordance rate regarding dysplasia.
These results demonstrate the limitations in correlating 
cytomorphology and histopathology in some cases of myeloid 
malignancies, even following stringent and repetitive diagnostic 
assessments. They emphasize the need for a comprehensive diagnostic 
review in a patient-for-patient setting when a myeloid malignancy is 
75 years old, male patient, final diagnosis: RAEB-1 in CM; RCMD in HP 
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Figure 1b. Patient’s diagnosis was RAEB-1 by cytomorphology but RCMD by 
histopathology.
1400 x Zoom, Staining in CM: May-Grünwald-Giemsa, staining of first picture in HP: 
Hematoxillin and Eosin, 2Second picture of HP: Immunhistochemistry CD34a
70 years old, female patient, final diagnosis: CMML-2 in CM; suspected MDS in HP 
CM1 
 
HP1,2 
 
 
Figure 1c. Patient’s diagnosis was CMML-2 by cytomorphology but suspected MDS by 
histopathology. 
1400 x Zoom, Staining in CM: May-Grünwald-Giemsa, staining of first picture in HP: 
Hematoxillin and Eosin, 2Second picture of HP: Immunhistochemistry CD34
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suspected or confirmed, especially in cases with borderline morphologic 
features. Finally, they suggest the value of including the clinical history 
(e.g. the dynamics of peripheral blood values, infections, medications, 
comorbidities, or other reasons for dysplasia/cytopenia [18]) and 
results of all relevant techniques such as cytogenetics, array comparative 
hybridization, FISH, and molecular genetics/NGS, to obtain the most 
appropriate diagnostic categorization in discrepant cases [10]. Finally, 
the role of flow cytometry for diagnosis and risk stratification for MDS 
patients is increasing [19].
Patients with myeloid malignancies with differing results of 
cytomorphologic and histopathologic assessment, remain a challenge 
for all those involved in the diagnostic and clinical aspects of patients’ 
care. Frequently, such discrepancies will result in excessive diagnostic 
work-up and therapeutic insecurity. This may result in re-evaluation 
or even interruption of implemented therapies and repetitive 
discussion of the respective cases amongst physicians, and lab staff. 
Interdisciplinary boards are therefore essential to try to reach a final 
consensus on diagnosis, especially in difficult cases of suspected or 
myeloid malignancy with borderline morphological features. The 
combination of cytomorphologic and histopathologic assessment 
with clinical and laboratory data as well as genetic parameters are 
essential cornerstones in order to achieve high diagnostic accuracy in 
an interdisciplinary setting. 
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